Gesamtlänge aller Episoden: 6 days 20 hours 21 minutes
Donna E. Reece, MD - Cases in Relapsed Refractory Multiple Myeloma: The Role of Anti-CD38–Based Regimens in an Evolving Canadian Landscape
Marwan Fakih, MD - Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
Ana C. Garrido-Castro, MD / Sarah L. Sammons, MD - TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Significance of the Construct
Normand Blais, MD - Adjuvant Immunotherapy in Patients With Solid Tumours: Addressing Challenges With System Capacity in the Canadian Healthcare Setting
Brandon Sheffield, MD, FRCPC - Identifying Actionable Targets in Solid Tumours: The Importance of Comprehensive Genomic Profiling
Elena Castro, MD, PhD - Radioligand Therapy and Therapeutic Sequencing in mCRPC
Rosalyn Juergens, MD, PhD - Why Precision Matters in NSCLC: Challenges and Solutions for Targeting Rare Oncogenic Driver Mutations in the Canadian Landscape
Steven Mark Taylor, MD, FRCS(C), FACS - Beyond Face Value: The Case for Considering Immunotherapy in Locally Advanced cSCC
Christine Simmons, MD, MSc, FRCPC - Managing HR+/HER2- Metastatic Breast Cancer in the Community: Optimizing Safety to Maximize Benefit
Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations